Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of PASylated nomacopan for geographic atrophy (GA) in dry age-related macular degeneration (dAMD)

Next Previous
Trial Profile

A clinical study of PASylated nomacopan for geographic atrophy (GA) in dry age-related macular degeneration (dAMD)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nomacopan (Primary)
  • Indications Dry macular degeneration
  • Focus Adverse reactions

Most Recent Events

  • 11 Jul 2023 According to an Akari Therapeutics media release, company plans submission of IND for treatment of geographic atrophy (GA) in the first half of 2024 and the start of clinical trials in the second half of 2024.
  • 04 Aug 2022 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top